Interacciones de Tirzepatida

Antidiabetic agents Hypoglycemia including fatal outcomes have been reported. (etiqueta de Ciprofloxacino, Interacciones medicamentosas)

Hypoglycemia Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications (see PRECAUTIONS , Drug Interactions ). (etiqueta de Cloroquina, Advertencias)

Diabetic ketoacidosis should be treated with insulin [see Warnings and Precautions (5.1) and Warnings and Precautions (5.2) ] . (etiqueta de Dapagliflozina y metformina, Contraindicaciones)

Oral hypoglycemics Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. (etiqueta de Fluconazol, Interacciones medicamentosas)

These conditions should be treated with insulin. (etiqueta de Glibenclamida, Contraindicaciones)

Diabetic ketoacidosis should be treated with insulin. (etiqueta de Glipizida y metformina, Contraindicaciones)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etiqueta de Hidroxicloroquina, Advertencias y precauciones)

To avoid medication errors between LEVEMIR and other insulins, instruct patients to always check the insulin label before each injection. (etiqueta de Insulina detemir, Advertencias y precauciones)

To avoid medication errors between LYUMJEV and other insulins, instruct patients to always check the insulin label before each injection. (etiqueta de Insulina lispro, Advertencias y precauciones)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etiqueta de Tirzepatida, Advertencia en recuadro)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etiqueta de Tirzepatida, Advertencia en recuadro)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etiqueta de Tirzepatida, Advertencia en recuadro)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etiqueta de Tirzepatida, Advertencia en recuadro)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etiqueta de Tirzepatida, Advertencia en recuadro)

Risk factors include high dose or overdose, rapid administration (see WARNINGS and DOSAGE AND ADMINISTRATION ), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). (etiqueta de Protamina, Advertencia en recuadro)

Diabetic ketoacidosis should be treated with insulin. (etiqueta de Saxagliptina y metformina, Contraindicaciones)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etiqueta de Tirzepatida, Advertencia en recuadro)

Monitor blood glucose in patients with diabetes and assess if antidiabetic agent dose modifications are required. (etiqueta de Abiraterona, Advertencias y precauciones)

When such drugs are withdrawn from patients receiving acarbose tablets in combination with sulfonylureas or insulin, patients should be observed closely for any evidence of hypoglycemia. (etiqueta de Acarbosa, Interacciones medicamentosas)

Diabetes and Hypoglycemia β-blockers may potentiate insulin-induced hypoglycemia and mask some of its manifestations such as tachycardia; however, dizziness and sweating are usually not significantly affected. (etiqueta de Acebutolol, Advertencias)

Consideration should be taken in patients being treated with antidiabetic agents. (etiqueta de Acetazolamida, Interacciones medicamentosas)

Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. (etiqueta de Ácido acetilsalicílico y dipiridamol, Interacciones medicamentosas)

Glyburide: In a trial of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose-lowering effect of glyburide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects. (etiqueta de Acitretina, Interacciones medicamentosas)

El alcohol puede causar un nivel bajo de azúcar en sangre con la insulina o las sulfonilureas, y el consumo elevado de alcohol con metformina aumenta el riesgo de acidosis láctica. (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin tablets. (etiqueta de Alogliptina, Advertencias y precauciones)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating Alogliptin and metformin HCl tablets. (etiqueta de Alogliptina y metformina, Advertencias y precauciones)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (etiqueta de Amlodipino y benazepril, Interacciones medicamentosas)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (etiqueta de Atazanavir, Advertencias y precauciones)

At recommended doses atenolol does not potentiate insulin-induced hypoglycemia and, unlike nonselective beta- blockers, does not delay recovery of blood glucose to normal levels. (etiqueta de Atenolol y clortalidona, Advertencias)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (etiqueta de Benazepril, Interacciones medicamentosas)

Antidiabetic agents: Dosage adjustment of antidiabetic drug may be required. (etiqueta de Benazepril e hidroclorotiazida, Interacciones medicamentosas)

Unlike nonselective beta-blockers, betaxolol does not prolong insulin-induced hypoglycemia. (etiqueta de Betaxolol, Advertencias)

Hypoglycemia: Consider a lower dose of insulin or insulin secretagogue to reduce risk of hypoglycemia when used in combination with bexagliflozin tablets. (etiqueta de Bexagliflozina, Advertencias y precauciones)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (etiqueta de Bexaroteno, Advertencias y precauciones)

Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. (etiqueta de Bisoprolol, Advertencias)

Also, latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose. (etiqueta de Bisoprolol e hidroclorotiazida, Advertencias)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (etiqueta de Brimonidina y timolol, Advertencias y precauciones)

Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules exceeds maximum recommended daily dosage. (etiqueta de Butalbital, ácido acetilsalicílico y cafeína, Interacciones medicamentosas)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (etiqueta de Butalbital, ácido acetilsalicílico, cafeína y codeína, Interacciones medicamentosas)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (etiqueta de Canagliflozina, Advertencias y precauciones)

Antidiabetic drugs (oral agents and insulin) − Dosage adjustment of the antidiabetic drug may be required. (etiqueta de Candesartán e hidroclorotiazida, Interacciones medicamentosas)

Closely monitor for adverse reactions of CYP2C9 substrates where minimal concentration changes may lead to serious adverse reactions when used concomitantly with XELODA (e.g., anticoagulants, antidiabetic drugs). (etiqueta de Capecitabina, Interacciones medicamentosas)

During the 8-week trial, serum insulin levels increased by 12 pmol/L in the VRAYLAR 1 mg to 2 mg per day group, 20 pmol/L in the VRAYLAR 2 mg to 4.5 mg per day group, and 8.5 pmol/L in the placebo group. (etiqueta de Cariprazina, Advertencias y precauciones)

Insulin and oral hypoglycemics action may be enhanced. (etiqueta de Carvedilol, Interacciones medicamentosas)

Oral Hypoglycemic Agents/Insulin: The concomitant use of clarithromycin tablets and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. (etiqueta de Claritromicina, Advertencias y precauciones)

Antidiabetic Drugs (Oral Agents and Insulin) - dosage adjustment of the antidiabetic drug may be required. (etiqueta de Clorotiazida, Interacciones medicamentosas)

…placebo) and when colesevelam hydrochloride was used in combination with pioglitazone (median increase 11% compared to placebo in combination with pioglitazone), sulfonylureas (median increase 18% compared to placebo in combination with sulfonylureas), and insulin (median increase 22% compared to placebo in combination with insulin) [see Adverse Reactions (6.1) ]. (etiqueta de Colesevelam, Advertencias y precauciones)

Caution should be exercised when used with antidiabetic drugs. (etiqueta de Danazol, Interacciones medicamentosas)

• Hypoglycemia: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with DAPAGLIFLOZIN TABLETS. (etiqueta de Dapagliflozina, Advertencias y precauciones)

Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required. (etiqueta de Darunavir, Advertencias y precauciones)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (etiqueta de Darunavir y cobicistat, Advertencias y precauciones)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Hyperglycemia Corticosteroids can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term therapy to diabetes mellitus, and may reduce the effect of the antidiabetic drugs. (etiqueta de Dexametasona, Advertencias y precauciones)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (etiqueta de Dorzolamida y timolol, Advertencias y precauciones)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. (etiqueta de Dulaglutida, Advertencias y precauciones)

The effects of increases in the concentration of the progestational component norgestimate are not fully known and can include increased risk of insulin resistance, dyslipidemia, acne, and venous thrombosis. (etiqueta de Elvitegravir, cobicistat, emtricitabina y tenofovir, Interacciones medicamentosas)

Hypoglycemia: Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia. (etiqueta de Empagliflozina, Advertencias y precauciones)

Hypoglycemia: Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia. (etiqueta de Empagliflozina y metformina, Advertencias y precauciones)

Anti-diabetic drugs (oral agents and insulin) Dosage adjustment of the anti-diabetic drug may be required. (etiqueta de Enalapril e hidroclorotiazida, Interacciones medicamentosas)

Antidiabetic drugs (e.g., oral agents, insulin): Dosage adjustment of the antidiabetic drug may be required (see Precautions ). (etiqueta de Espironolactona e hidroclorotiazida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (etiqueta de Exenatida, Advertencias y precauciones)

• A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (etiqueta de Fentermina, Advertencias y precauciones)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (etiqueta de Fludrocortisona, Interacciones medicamentosas)

As is true with many other types of medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with PROZAC is instituted or discontinued. (etiqueta de Fluoxetina, Advertencias y precauciones)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (etiqueta de Fosamprenavir, Advertencias y precauciones)

Insulin requirements in diabetic patients may be increased, decreased, or unchanged. (etiqueta de Fosinopril e hidroclorotiazida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (etiqueta de Tirzepatida, Advertencias y precauciones)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (etiqueta de Tirzepatida, Advertencias y precauciones)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (etiqueta de Tirzepatida, Advertencias y precauciones)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (etiqueta de Glucagón, Advertencias y precauciones)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (etiqueta de Hidroclorotiazida, Interacciones medicamentosas)

Antidiabetic Agents Clinical Impact: Corticosteroids in supraphysiologic doses may increase blood glucose concentrations. (etiqueta de Hidrocortisona, Interacciones medicamentosas)

Hydroxyurea may falsely elevate sensor glucose results from certain continuous glucose monitoring (CGM) systems and may lead to hypoglycemia if sensor glucose results are relied upon to dose insulin. (etiqueta de Hidroxicarbamida (hidroxiurea), Advertencias y precauciones)

Increase frequency of glucose monitoring with changes to: insulin dosage, concomitantly administered glucose lowering medications, meal pattern, physical activity; and in patients with renal or hepatic impairments and hypoglycemia unawareness ( 5. (etiqueta de Insulina asparta, Advertencias y precauciones)

The risk of hypoglycemia after an injection is related to the duration of action of the insulin [see Clinical Pharmacology ( 12.2 )] and, in general, is highest when the glucose lowering effect of the insulin is maximal. (etiqueta de Insulina degludec, Advertencias y precauciones)

For patients with type 2 diabetes, dosage adjustments of concomitant oral and antidiabetic products may be needed. (etiqueta de Insulina glargina, Advertencias y precauciones)

For patients with type 2 diabetes mellitus, oral antidiabetic treatment dosage modifications may be needed. (etiqueta de Insulina regular (humana), Advertencias y precauciones)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (etiqueta de Irbesartán e hidroclorotiazida, Interacciones medicamentosas)

Antidiabetic Drugs Repaglinide Saxagliptin Monitor for adverse reactions. (etiqueta de Itraconazol, Interacciones medicamentosas)

Antidiabetics repaglinide, saxagliptin Antihelmintics and Antiprotozoals praziquantel Antimigraine Drugs ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine) eletriptan Ergot alkaloids: The potential increase in plasma concentrations of ergot alkaloids when coadministered with ketoconazole tablets… (etiqueta de Ketoconazol, Interacciones medicamentosas)

Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (etiqueta de Lanreotida, Advertencias y precauciones)

Blood Glucose Disturbances Fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (etiqueta de Levofloxacino, Advertencias y precauciones)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (etiqueta de Linagliptina, Advertencias y precauciones)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating JENTADUETO XR. (etiqueta de Linagliptina y metformina, Advertencias y precauciones)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (etiqueta de Linezolid, Advertencias y precauciones)

• Hypoglycemia : Adult patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. (etiqueta de Liraglutida, Advertencias y precauciones)

Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (etiqueta de Lisinopril, Interacciones medicamentosas)

Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (etiqueta de Lisinopril e hidroclorotiazida, Interacciones medicamentosas)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (etiqueta de Lopinavir y ritonavir, Advertencias y precauciones)

Antidiabetic drugs: dosage adjustment of antidiabetic may be required. (etiqueta de Losartán e hidroclorotiazida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues : Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. (etiqueta de Metformina, Advertencias y precauciones)

Antidiabetics : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Metilprednisolona, Interacciones medicamentosas)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (etiqueta de Metiltestosterona, Interacciones medicamentosas)

Insulin Clinical Impact Increased GI motility by metoclopramide may increase delivery of food to the intestines and increase blood glucose. (etiqueta de Metoclopramida, Interacciones medicamentosas)

Insulin And Oral Antidiabetic Agents See Glucose Tolerance under PRECAUTIONS , General . (etiqueta de Metolazona, Interacciones medicamentosas)

Antidiabetic drugs: Dosage adjustment may be required. (etiqueta de Metoprolol e hidroclorotiazida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Antidiabetic agents Carefully monitor blood glucose. (etiqueta de Moxifloxacino, Interacciones medicamentosas)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (etiqueta de Nadolol, Advertencias)

Use of Antidiabetic Medications: Weight loss may cause hypoglycemia. (etiqueta de Naltrexona y bupropión, Advertencias y precauciones)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (etiqueta de Tirzepatida, Advertencias y precauciones)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (etiqueta de Octreotida, Advertencias y precauciones)

Fluoroquinolones have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (etiqueta de Ofloxacino, Advertencias)

• Antidiabetic drugs: Dosage adjustment may be required. (etiqueta de Olmesartán e hidroclorotiazida, Interacciones medicamentosas)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (etiqueta de Olmesartán, amlodipino e hidroclorotiazida, Interacciones medicamentosas)

A reduction in dose of oral hypoglycemic medication (e.g., sulfonylureas) or insulin may be required in some patients [see Clinical Studies (14) ] . (etiqueta de Orlistat, Advertencias y precauciones)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (etiqueta de Pindolol, Advertencias)

Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk. (etiqueta de Pioglitazona, Advertencias y precauciones)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (etiqueta de Tirzepatida, Advertencias y precauciones)

Combination use with insulin and use in congestive heart failure NYHA Class I and II may increase risk. (etiqueta de Pioglitazona y metformina, Advertencias y precauciones)

Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Prednisolona, Interacciones medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (etiqueta de Prednisona, Interacciones medicamentosas)

Monitor patients for the development of edema when co-administering LYRICA CR and thiazolidinedione antidiabetic agents. (etiqueta de Pregabalina, Advertencias y precauciones)

Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Hypoglycemia Quinine stimulates release of insulin from the pancreas, and patients, especially pregnant women, may experience clinically significant hypoglycemia. (etiqueta de Quinina, Advertencias y precauciones)

Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia. (etiqueta de Tirzepatida, Advertencias y precauciones)

Decrease exposure Digitoxin Decrease exposure Fluoroquinolones Pefloxacin Administered with rifampin 900 mg daily Decrease exposure Moxifloxacin , Decrease exposure Oral Hypoglycemic Agents (e.g., sulfonylureas) Glyburide Decrease exposure Rifampin may worsen glucose control of glyburide. (etiqueta de Rifampicina, Interacciones medicamentosas)

…Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines… (etiqueta de Rifapentina, Interacciones medicamentosas)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (etiqueta de Ritonavir, Advertencias y precauciones)

Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (etiqueta de Salsalato, Interacciones medicamentosas)

• Hypoglycemia with Concomitant Use of Insulin or Insulin Secretagogues: Consider a lower dosage of insulin or insulin secretagogue when used in combination wtih Saxagliptin tablets ( 5.3 ) (etiqueta de Saxagliptina, Advertencias y precauciones)

• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin : May increase the risk of hypoglycemia, including severe hypoglycemia. (etiqueta de Semaglutida, Advertencias y precauciones)

Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. (etiqueta de Sitagliptina, Advertencias y precauciones)

Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. (etiqueta de Sitagliptina y metformina, Advertencias y precauciones)

Glucose Intolerance and Diabetes Mellitus: HUMATROPE may decrease insulin sensitivity, particularly at higher doses. (etiqueta de Somatropina, Advertencias y precauciones)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (etiqueta de Sotalol, Interacciones medicamentosas)

Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. (etiqueta de Sulfametoxazol y trimetoprima, Interacciones medicamentosas)

• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

Antidiabetic drugs: Dosage adjustment may be required ( 7.6 ) (etiqueta de Telmisartán e hidroclorotiazida, Interacciones medicamentosas)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (etiqueta de Temsirolimus, Advertencias y precauciones)

Insulin: In patients with diabetes, concomitant use with TLANDO may decrease blood glucose and insulin requirements ( 7.1) . (etiqueta de Testosterona, Interacciones medicamentosas)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (etiqueta de Timolol, Advertencias y precauciones)

(See PRECAUTIONS . ) Antidiabetic Agents Concomitant use of ACE inhibitors and antidiabetic medicines (insulin or oral hypoglycemic agents) may cause an increased blood glucose lowering effect with greater risk of hypoglycemia. (etiqueta de Trandolapril, Interacciones medicamentosas)

Hypoglycemia in Diabetic Patients Some MAOIs have contributed to hypoglycemic episodes in diabetic patients receiving insulin or other blood-glucose-lowering agents. (etiqueta de Tranilcipromina, Advertencias y precauciones)

Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (etiqueta de Triamcinolona, Interacciones medicamentosas)

Infusion of glucose and insulin has also been used to treat hyperkalemia. (etiqueta de Triamtereno, Advertencias y precauciones)

Oral Hypoglycemic Drugs Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. (etiqueta de Triamtereno e hidroclorotiazida, Interacciones medicamentosas)

Hydrochlorothiazide: When administered concurrently, the following drugs may interact with thiazide diuretics: Antidiabetic Drugs (oral agents and insulin) - Dosage adjustment of the antidiabetic drug may be required. (etiqueta de Valsartán e hidroclorotiazida, Interacciones medicamentosas)

• Effect of Smoking Cessation on Other Drugs: Pharmacokinetics or pharmacodynamics of certain drugs (e.g., theophylline, warfarin, insulin) may be altered, necessitating dose adjustment. (etiqueta de Vareniclina, Interacciones medicamentosas)

Sulfonylurea Oral Hypoglycemics (CYP2C9 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. (etiqueta de Voriconazol, Interacciones medicamentosas)

Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with ZEPBOUND. (etiqueta de Tirzepatida, Interacciones medicamentosas)

Such measures include the intravenous administration of sodium bicarbonate solution or oral or parenteral glucose with a rapid-acting insulin preparation. (etiqueta de Amilorida, Advertencias)

Antidiabetic drug requirements (i.e., insulin) may be altered. (etiqueta de Anfepramona, Interacciones medicamentosas)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (etiqueta de Bupropión, Advertencias y precauciones)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (etiqueta de Clozapina, Advertencias y precauciones)

Insulin and Oral Hypoglycemic Medications Requirements may be altered. (etiqueta de Fendimetrazina, Interacciones medicamentosas)

Hyperglycemia Hyperglycemia, resulting from the drug’s inhibitory effects on insulin release, has been reported. (etiqueta de Fenitoína, Advertencias y precauciones)

Hyperglycemia Hyperglycemia, resulting from the inhibitory effect of phenytoin (the active metabolite of CEREBYX) on insulin release, has been reported. (etiqueta de Fosfenitoína, Advertencias y precauciones)

Oral Hypoglycemic Agents In pharmacokinetic studies of lovastatin in hypercholesterolemic non-insulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide (see CLINICAL PHARMACOLOGY , Clinical Studies in Adults ). (etiqueta de Lovastatina, Interacciones medicamentosas)

In an uncontrolled open-label trial of CAPLYTA for up to 1 year in adult patients with stable schizophrenia, the percentages of patients with shifts in fasting glucose and insulin values from normal to high were 8% and 12%, respectively. (etiqueta de Lumateperona, Advertencias y precauciones)

Administer INCRELEX shortly before or after a meal or snack, because it has insulin-like hypoglycemic effects. (etiqueta de Mecasermina, Advertencias y precauciones)

Insulin requirements in diabetes mellitus may be altered in association with the use of methamphetamine and the concomitant dietary regimen. (etiqueta de Metanfetamina, Interacciones medicamentosas)

Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out. (etiqueta de Miconazol, Interacciones medicamentosas)

…been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (etiqueta de Milrinona, Interacciones medicamentosas)

Moexipril hydrochloride has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H 2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. (etiqueta de Moexipril, Interacciones medicamentosas)

Glucose Lowering Drugs Pioglitazone: Co-administration of pioglitazone for 7 days with 30 mg nifedipine ER administered orally q.d. for 4 days to male and female volunteers resulted in least square mean (90% CI) values for unchanged nifedipine of 0.83 (0.73-0.95) for C max and 0.88 (0.80-0.96) for AUC relative to nifedipine monotherapy. (etiqueta de Nifedipino, Precauciones)

…been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine,… (etiqueta de Prazosina, Interacciones medicamentosas)

Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (etiqueta de Sulfadiazina, Interacciones medicamentosas)

Administration of intravenous calcium, bicarbonate, and glucose with insulin, with hyperventilation have resulted in successful resuscitation in some of the reported cases. (etiqueta de Suxametonio (succinilcolina), Advertencias y precauciones)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (etiqueta de Telmisartán y amlodipino, Interacciones medicamentosas)

Hypoglycemic Agents: In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. (etiqueta de Tolmetina, Interacciones medicamentosas)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (etiqueta de Ziprasidona, Advertencias y precauciones)

Glyburide Clinical Impact: While oxaprozin does alter the pharmacokinetics of glyburide, coadministration of oxaprozin to type II non-insulin dependent diabetic patients did not affect the area under the glucose concentration curve nor the magnitude or duration of control. (etiqueta de Oxaprozina, Interacciones medicamentosas)

Oral hypoglycemic agents Although sulindac and its sulfide metabolite are highly bound to protein, studies in which sulindac was given at a dose of 400 mg daily, have shown no clinically significant interaction with oral hypoglycemic agents. (etiqueta de Sulindaco, Interacciones medicamentosas)

Other interactions: Vardenafil hydrochloride tablets had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters). (etiqueta de Vardenafilo, Interacciones medicamentosas)